Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TAK vs ELAN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TAK Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)

TAK Overall Winner 6-Pillar Tally: TAK 3 – 2 ELAN (1 Tie) Matrix Metrics: TAK 8 – 2 ELAN

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Elanco Animal Health Incorporated (ELAN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas ELAN carries 35.7/100 (SELL) at $26.36 (20.8x Forward P/E, 7.7% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TAK vs ELAN
TAK NYSE Head-to-Head Winner
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 73
RSI-14: 73.1 · SMA20: $20.72 · SMA50: $19.46
ELAN NYSE
Elanco Animal Health Incorporated Common Stock
Pharmaceutical Preparations
$26.36
-1.59% 1D
Market Cap $13.2B
TTM Revenue $5.15B
Forward P/E 20.8x
Beta / 30D Vol 1.27β · 49% Vol
Unified Composite Score
35.7 / 100 SELL
Tech 50.0 Fund 37.0 Flow 71.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.0% over 20 days), RSI 67
RSI-14: 66.9 · SMA20: $24.42 · SMA50: $23.42

6-Pillar Scorecard Institutional Category Breakdown (TAK 3 – 2 ELAN)

Columns: Metric · TAK · ELAN
1. Valuation Multiples TAK
Forward P/E 12.7x 20.8x
Trailing P/E N/M 19.6x
PEG Ratio 0.47x 8.94x
EV / Revenue 2.6x 3.2x
2. Growth & Scale ELAN
Revenue Growth (YoY) +6.7% +11.3%
Earnings Growth (YoY) -9.8% +440.5%
TTM Revenue (USD) $25.7B $5.15B
Market Cap $67.5B $13.2B
3. Profitability & Quality TAK
Gross Margin 64.8% 56.2%
Operating Margin 16.6% 7.7%
Net Profit Margin 0.9% -2.9%
Return on Equity (ROE) 0.6% -2.2%
4. Balance Sheet & Cash Flow TAK
Cash Generation (TTM) $7.48B EBITDA $408M
Cash Flow Margin 29.1% EBITDA Mgn 7.9%
Net Cash / Leverage $14.68 Book/Sh · 0.6% ROE $3.24B Net Debt (0.56x D/E)
Dividend Yield 2.92% None (0.00%)
5. Options & Positioning ELAN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 22.4% (5th %ile) 36.1% (1st %ile)
Put/Call OI Skew Thin ADR Chain 13.39x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity 48.2% of Rev ($12.4B) 48.5% of Rev ($2.50B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TAK (8) vs ELAN (2)
Institutional Metric TAK ELAN Criterion Row Edge
Market Capitalization
Scale
$67.5B $13.2B Larger Scale TAK
Trailing P/E Ratio
Valuation
N/M 19.6x Lower Multiple ELAN
Forward P/E Ratio
Valuation
12.7x 20.8x Lower Multiple TAK
Revenue Growth (YoY)
Growth
+6.7% +11.3% Higher Growth ELAN
Operating Margin (TTM)
Profitability
16.6% 7.7% Higher Margin TAK
Net Profit Margin
Profitability
0.9% -2.9% Higher Margin TAK
Return on Equity (ROE)
Capital Efficiency
0.6% -2.2% Higher ROE TAK
52-Week Range Position
Momentum
97% ($14–$22) 81% ($19–$28) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
-0.02β · 22% Vol 1.27β · 49% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD) 35.7 / 100 (SELL) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$25.7B $5.15B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.8% 56.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.47x PEG · 2.6x EV/Rev 8.94x PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) $408M ($3.24B Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ELAN +2.02 pp
TAK: +9.89% · ELAN: +11.91%
3M Horizon TAK +8.27 pp
TAK: +19.75% · ELAN: +11.48%
6M Horizon ELAN +1.79 pp
TAK: +30.45% · ELAN: +32.24%
1Y Horizon TAK +31.94 pp
TAK: +51.79% · ELAN: +19.85%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs ELAN. Trailing 12-month operating profitability (TAK 16.6% vs ELAN 7.7%) and valuation multiples (TAK 12.7x vs ELAN 20.8x Forward P/E) are benchmarked directly in Pillar 4 below.

TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x
ELAN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.15B
Gross Margin56.2%
Op. Margin7.7%
ROE / Fwd P/E-2.2% · 20.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ELAN CONSOLIDATION
76d in phase · OBV ACCUMULATION
Current IV 36.1%
IV Percentile 1st %ile
Put/Call OI Skew 13.39x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact ELAN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published
ELAN Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $13.2B market capitalization and 7.7% operating margin.
OpEx & R&D Reinvestment 48.5% of Rev ($2.50B)
90D Engineering Disclosures 0 Published

Investor FAQ TAK vs ELAN Key Questions & Quantitative Answers

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Elanco Animal Health Incorporated (ELAN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas ELAN carries 35.7/100 (SELL) at $26.36 (20.8x Forward P/E, 7.7% operating margin). Technically, TAK sits in a Markup phase (RSI 73.1, UNCLASSIFIED options structure) and ELAN sits in a Markup phase (RSI 66.9, CONSOLIDATION options structure).

ELAN leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with ELAN at +11.3% YoY revenue growth and +440.5% YoY earnings growth on $5.15B TTM revenue (56.2% gross margin, 7.7% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $5.15B for ELAN. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 48.5% of Rev ($2.50B) (0 disclosures) for ELAN.

TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas ELAN trades at 20.8x Forward P/E, 19.6x Trailing P/E, 8.94x PEG, and 3.2x EV/Revenue (7.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus ELAN (-2.2% ROE) capital efficiency.

In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, ELAN carries 36.1% implied volatility (1st %ile, Compressed (<25th %ile)), a 13.39x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.27β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Elanco Animal Health Incorporated Common Stock (ELAN) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.